#1 HbA1c
Insulin Therapies → HbA1c
Evidence Intelligence™
- EvidenceScore™
- 88
- Strong
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 73
- generally_consistent
Estudios de apoyo: Basado en 15 estudios
Explore evidenceMedications
Last updated: 29 de agosto de 2026
Key takeaway
Medications has evidence across 10 diabetes-related outcomes, with strongest support for HbA1c, Body Weight and HbA1c.
Evidence status
Moderate ResearchEvidence Strength: 60/100
Related Evidence Topics
Evidence Intelligence™
Every evidence topic is generated from structured relationships across diabetes research, including topics, interventions, outcomes, and individual studies.
1,249
Evidence relationships
1,550
Studies reviewed
36
Outcomes evaluated
Strongest evidence area
HbA1c
Top Interventions
Showing grouped evidence. Expand in Evidence Explorer for detailed intervention-outcome pairs.Open Evidence Explorer
| Rank | Outcome group | EvidenceScore™ | ImpactScore™ | Consistency | Studies | Effectiveness | Action |
|---|---|---|---|---|---|---|---|
| #1 | HbA1c | 88/100Strong | 75/100Positive | 73/100generally_consistent | 15 | moderate_positive | Explore evidence |
| #2 | Body Weight | 86/100Strong | 83/100Positive | 89/100consistent | 9 | moderate_positive | Explore evidence |
| #3 | HbA1c | 86/100Strong | 82/100Positive | 89/100consistent | 22 | moderate_positive | Explore evidence |
| #4 | HbA1c | 86/100Strong | 90/100Very Positive | 94/100consistent | 33 | strong_positive | Explore evidence |
| #5 | HbA1c | 86/100Strong | 96/100Very Positive | 100/100consistent | 11 | strong_positive | Explore evidence |
| #6 | Body Weight | 85/100Strong | 81/100Positive | 71/100generally_consistent | 8 | moderate_positive | Explore evidence |
| #7 | Fasting Glucose | 85/100Strong | 73/100Positive | 35/100mixed | 11 | moderate_positive | Explore evidence |
| #8 | Body Weight | 85/100Strong | 85/100Positive | 97/100consistent | 33 | moderate_positive | Explore evidence |
| #9 | CGM Time in Range | 85/100Strong | 85/100Very Positive | 78/100consistent | 10 | strong_positive | Explore evidence |
| #10 | Fasting Glucose | 85/100Strong | 78/100Positive | 75/100consistent | 9 | moderate_positive | Explore evidence |
#2 Body Weight
SGLT2 Inhibitors → Body Weight
Evidence Intelligence™
- EvidenceScore™
- 86
- Strong
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 89
- consistent
Estudios de apoyo: Basado en 9 estudios
Explore evidence#3 HbA1c
SGLT2 Inhibitors → HbA1c
Evidence Intelligence™
- EvidenceScore™
- 86
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 89
- consistent
Estudios de apoyo: Basado en 22 estudios
Explore evidence#4 HbA1c
GLP-1 Receptor Agonists → HbA1c
Evidence Intelligence™
- EvidenceScore™
- 86
- Strong
- ImpactScore™
- 90
- Very Positive
- ConsistencyScore™
- 94
- consistent
Estudios de apoyo: Basado en 33 estudios
Explore evidence#5 HbA1c
DPP-4 Inhibitors → HbA1c
Evidence Intelligence™
- EvidenceScore™
- 86
- Strong
- ImpactScore™
- 96
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 11 estudios
Explore evidence#6 Body Weight
DPP-4 Inhibitors → Body Weight
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 81
- Positive
- ConsistencyScore™
- 71
- generally_consistent
Estudios de apoyo: Basado en 8 estudios
Explore evidence#7 Fasting Glucose
Metformin Therapies → Fasting Glucose
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 73
- Positive
- ConsistencyScore™
- 35
- mixed
Estudios de apoyo: Basado en 11 estudios
Explore evidence#8 Body Weight
GLP-1 Receptor Agonists → Body Weight
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 85
- Positive
- ConsistencyScore™
- 97
- consistent
Estudios de apoyo: Basado en 33 estudios
Explore evidence#9 CGM Time in Range
Insulin Therapies → CGM Time in Range
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 85
- Very Positive
- ConsistencyScore™
- 78
- consistent
Estudios de apoyo: Basado en 10 estudios
Explore evidence#10 Fasting Glucose
Insulin Therapies → Fasting Glucose
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 78
- Positive
- ConsistencyScore™
- 75
- consistent
Estudios de apoyo: Basado en 9 estudios
Explore evidencePractical Questions
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Which outcomes have the strongest evidence for Medications?
evidence strengthStrong Evidence
HbA1c and Body weight have the strongest available evidence signals for Medications.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.6 | strong positive | ConsistencyScore™ Consistent | 24 studies
- 2
Body weight
EvidenceScore™ Strong | EvidenceScore™ 82.7 | strong positive | ConsistencyScore™ Consistent | 12 studies
Why this answer: This answer is based on 25 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
What outcomes does Medications appear to affect most often?
most studiedEmerging Evidence
HbA1c, Body weight, and Fasting Plasma Glucose (FPG) are among the most studied areas in relation to Medications.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.6 | strong positive | ConsistencyScore™ Consistent | 117 studies
- 2
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.5 | moderate positive | ConsistencyScore™ Consistent | 58 studies
- 3
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 83.9 | moderate positive | ConsistencyScore™ Generally Consistent | 39 studies
Why this answer: This answer is based on 128 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Where are results mixed or inconsistent for Medications?
consistency issuesModerate Evidence
Results are mixed or unclear for Coefficient of variation, Time below range, and Time in range in relation to Medications.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The evidence includes both beneficial and harmful or worsening results.
Ranked evidence signals
- 1
All-cause mortality
EvidenceScore™ Strong | EvidenceScore™ 82.9 | weak positive | ConsistencyScore™ Mixed | 8 studies
- 2
Body weight
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Mixed | 10 studies
- 3
Glucose iAUC (OGTT)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Mixed | 6 studies
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Which outcomes need more research for Medications?
research gapsEmerging Evidence
Meibomian gland quality (MGQ), Non-invasive tear breakup time (NITBUT), and Ocular Surface Disease Index (OSDI) Score Reduction need more research in relation to Medications.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Meibomian gland quality (MGQ)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Non-invasive tear breakup time (NITBUT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 3
Ocular Surface Disease Index (OSDI) Score Reduction
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
How does HbA1c compare with Body weight for Medications?
compareStrong Evidence
Body weight and HbA1c have available evidence for Medications, but the comparison requires review of the underlying studies.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.6 | strong positive | ConsistencyScore™ Consistent | 12 studies
- 2
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.5 | moderate positive | ConsistencyScore™ Consistent | 9 studies
Why this answer: This answer is based on 13 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Outcomes Influenced by Medications
Outcomes most commonly studied in relation to medications interventions.
HbA1c Reduction
EvidenceScore™ 65/100
Evidence related to lowering or improving HbA1c/A1C in diabetes management.
173 Studies
Cardiovascular Risk
EvidenceScore™ 63/100
Evidence related to cardiovascular risk, cardiovascular events, ASCVD risk, vascular function, functional capacity, and mortality outcomes in diabetes studies.
62 Studies
Weight Loss
EvidenceScore™ 63/100
Evidence related to body weight reduction, BMI improvement, waist circumference, and body composition changes.
155 Studies
Glycemic Control
EvidenceScore™ 62/100
Evidence related to blood glucose control, fasting glucose, postprandial glucose, glucose variability, and time in range.
175 Studies
Inflammatory and Vascular Markers
EvidenceScore™ 60/100
Evidence related to inflammatory, oxidative stress, endothelial, and vascular biomarkers measured in diabetes studies.
12 Studies
Bone Mineral Density
EvidenceScore™ 59/100
Evidence related to bone mineral density and bone mineral content outcomes in diabetes studies.
5 Studies
Latest Research
Semaglutide reduces insulin doses in type 1 diabetes
Published: 1 de mayo de 2026
int-semaglutide
out-basal-insulin-doseout-bolus-insulin-dose
Nimba Amalakyadi Improves Glycemic Control in Type 2 Diabetes
Published: 13 de marzo de 2026
int-metformin
out-fasting-plasma-glucoseout-glucose-iauc-ogtt
Corticosteroids may help manage cytokine release syndrome during teplizumab therapy
Published: 1 de marzo de 2026
int-teplizumab
out-c-peptideout-cytokine-release-syndrome
Canagliflozin improves myocardial fibrosis in type 2 diabetes
Published: 24 de febrero de 2026
int-canagliflozin
out-catecholamineout-extracellular-volume
Artificial pancreas may improve glucose control in type 1 diabetes
Published: 20 de enero de 2026
int-insulin-therapy
out-blood-glucoseout-hypoglycemia-events
Pentoxifylline improves kidney and heart health in diabetic patients
Published: 6 de enero de 2026
int-pentoxifylline
out-albuminuriaout-estimated-glomerular-filtration-rate
Mulberry twig alkaloids improve glucose control in type 2 diabetes
Published: 1 de enero de 2026
int-mulberry-twig-alkaloids-sz-a
out-blood-glucoseout-body-weight
Semaglutide with Insulin Improves Diabetes Control and Kidney Health
Published: 1 de enero de 2026
int-insulin-therapy
out-24-hour-urinary-protein-24huprout-adverse-events-incidence
Canagliflozin slows kidney function decline in type 2 diabetes.
Published: 1 de enero de 2026
int-canagliflozin
out-arterial-stiffness-progressionout-bmi
Baseline features predict exenatide efficacy in type 2 diabetes
Published: 1 de enero de 2026
int-exenatide
out-alanine-aminotransferase-altout-aspartate-aminotransferase
Evidence Landscape
Evidence landscape
Each bubble represents an evidence relationship. Position shows effectiveness and EvidenceScoreâ„¢; size reflects study volume.
- Strong evidence
- Moderate evidence
- Limited evidence
Evidence Workspace
Create your evidence workspace
Save evidence topics and organize the research that matters to you.